A/DT
Variant/JJ
in/IN
RUNX3/NN
Is/VBZ
Associated/VBN
with/IN
the/DT
Risk/NN
of/IN
Ankylosing/JJ
Spondylitis/NN
in/IN
Koreans/NNS
./.
====================
Ankylosing/VBG
spondylitis/NN
(/(
AS/JJ
)/)
is/VBZ
a/DT
chronic/JJ
autoinflammatory/JJ
disease/NN
that/DT
affects/VBZ
the/DT
spine/NN
and/CC
sacroiliac/JJ
joints/NNS
./.
====================
Regarding/VBG
its/PRP$
etiology/NN
,/,
although/IN
HLA-B27/NN
is/VBZ
known/VBN
to/TO
be/VB
the/DT
strongest/JJS
genetic/JJ
factor/NN
of/IN
AS/JJ
,/,
much/RB
evidence/NN
suggests/VBZ
the/DT
potential/JJ
contribution/NN
of/IN
non-MHC/JJ
genes/NNS
to/TO
the/DT
susceptibility/NN
to/TO
AS/JJ
./.
====================
Most/JJS
of/IN
these/DT
non-MHC/JJ
genes/NNS
have/VBP
been/VBN
discovered/VBN
in/IN
non-Asian/JJ
populations/NNS
;/:
however/RB
,/,
just/RB
some/DT
of/IN
them/PRP
have/VBP
been/VBN
validated/VBN
in/IN
Koreans/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
aimed/VBD
to/TO
identify/VB
additional/JJ
AS-associated/JJ
single-nucleotide/JJ
polymorphism/NN
(/(
SNP/NN
)/)
candidates/NNS
by/IN
replicating/VBG
the/DT
candidate/NN
SNPs/NNS
in/IN
Korean/JJ
AS/JJ
patients/NNS
and/CC
healthy/JJ
controls/NNS
./.
====================
For/IN
this/DT
,/,
we/PRP
selected/VBD
three/CD
SNPs/NNS
(/(
rs11249215/NN
in/IN
RUNX3/NN
,/,
rs6556416/NN
in/IN
IL12B/NN
,/,
and/CC
rs8070463/NN
in/IN
TBKBP1/NN
)/)
,/,
which/WDT
were/VBD
previously/RB
reported/VBN
as/IN
risk/NN
factors/NNS
of/IN
AS/JJ
but/CC
have/VBP
not/RB
been/VBN
studied/VBN
in/IN
Koreans/NNS
,/,
and/CC
performed/VBN
genotyping/VBG
assays/NNS
using/VBG
a/DT
total/JJ
of/IN
1138/CD
Korean/JJ
samples/NNS
(/(
572/CD
AS/JJ
patients/NNS
and/CC
566/CD
healthy/JJ
controls/NNS
)/)
./.
====================
Of/IN
the/DT
three/CD
SNP/NN
candidates/NNS
,/,
one/CD
SNP/NN
in/IN
RUNX3/NN
(/(
rs11249215/NN
)/)
was/VBD
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
AS/JJ
(/(
odds/NNS
ratio/NN
,/,
1.31/CD
;/:
95/CD
%/NN
confidence/NN
interval/JJ
,/,
1.02/CD
to/TO
1.68/CD
,/,
p/NN
=/JJ
0.03/CD
)/)
./.
====================
These/DT
results/NNS
will/MD
be/VB
helpful/JJ
in/IN
elucidating/VBG
the/DT
pathogenesis/NN
of/IN
AS/JJ
and/CC
may/MD
be/VB
useful/JJ
for/IN
developing/VBG
AS/JJ
risk/NN
prediction/NN
models/NNS
in/IN
Koreans/NNS
./.
====================
Ankylosing/VBG
spondylitis/NN
(/(
AS/JJ
)/)
is/VBZ
a/DT
type/NN
of/IN
chronic/JJ
autoinflammatory/JJ
disease/NN
that/DT
affects/VBZ
the/DT
spine/NN
and/CC
sacroiliac/JJ
joints/NNS
./.
====================
The/DT
pathogenesis/NN
of/IN
AS/JJ
is/VBZ
not/RB
clear/JJ
;/:
however/RB
,/,
it/PRP
is/VBZ
believed/VBN
to/TO
involve/VB
a/DT
combination/NN
of/IN
genetic/JJ
and/CC
environmental/JJ
factors/NNS
./.
====================
Among/IN
them/PRP
,/,
human/JJ
leukocyte/NN
antigen/NN
B27/NN
(/(
HLA-B27/NN
)/)
is/VBZ
the/DT
strongest/JJS
genetic/JJ
factor/NN
of/IN
AS/JJ
./.
====================
More/RBR
than/IN
80/CD
%/NN
to/TO
90/CD
%/NN
of/IN
patients/NNS
with/IN
AS/JJ
express/VBP
HLA-B27/NN
,/,
and/CC
the/DT
association/NN
between/IN
HLA-B27/NN
and/CC
AS/JJ
has/VBZ
been/VBN
identified/VBN
in/IN
many/JJ
ethnic/JJ
groups/NNS
[/(
1/CD
]/)
./.
====================
However/RB
,/,
only/RB
a/DT
small/JJ
portion/NN
of/IN
HLA-B27–positive/JJ
individuals/NNS
(/(
</JJR
5/CD
%/NN
)/)
develop/VBP
AS/JJ
,/,
suggesting/VBG
a/DT
potential/JJ
contribution/NN
of/IN
non-MHC/JJ
genes/NNS
to/TO
the/DT
susceptibility/NN
to/TO
AS/JJ
[/(
2/CD
]/)
./.
====================
A/DT
number/NN
of/IN
genome-wide/NN
association/NN
studies/NNS
(/(
GWASs/NNS
)/)
of/IN
single-nucleotide/JJ
polymorphisms/NNS
(/(
SNPs/NNS
)/)
have/VBP
identified/VBN
non-MHC/JJ
genes/NNS
associated/VBN
with/IN
AS/JJ
,/,
such/JJ
as/IN
IL-12B/NN
,/,
ERAP1/NN
,/,
RUNX3/NN
,/,
IL1R2/NN
,/,
and/CC
ANTXR2/NN
[/(
3456/CD
]/)
./.
====================
In/IN
addition/NN
to/TO
SNPs/NNS
,/,
through/IN
genomewide/NN
copy/NN
number/NN
variant/JJ
(/(
CNV/NN
)/)
analysis/NN
,/,
CNVs/NNS
associated/VBN
with/IN
AS/JJ
have/VBP
also/RB
been/VBN
identified/VBN
[/(
7/CD
]/)
./.
====================
These/DT
AS-associated/JJ
non-MHC/JJ
genes/NNS
support/VBP
the/DT
contribution/NN
of/IN
non-MHC/JJ
genes/NNS
to/TO
the/DT
susceptibility/NN
to/TO
AS/JJ
./.
====================
They/PRP
can/MD
also/RB
be/VB
valuable/JJ
markers/NNS
of/IN
the/DT
development/NN
of/IN
AS/JJ
./.
====================
From/IN
a/DT
clinical/JJ
point/NN
of/IN
view/NN
,/,
the/DT
identification/NN
of/IN
early/JJ
AS/JJ
before/IN
the/DT
appearance/NN
of/IN
radiological/JJ
changes/NNS
in/IN
the/DT
patient/NN
's/POS
spine/NN
or/CC
sacroiliac/JJ
joint/NN
is/VBZ
important/JJ
,/,
because/IN
current/JJ
treatment/NN
options/NNS
,/,
such/JJ
as/IN
tumor/NN
necrosis/NN
factor-α/JJ
(/(
TNF-α/NN
)/)
inhibitors/NNS
and/CC
nonsteroidal/JJ
anti-inflammatory/JJ
drugs/NNS
,/,
after/IN
these/DT
changes/NNS
have/VBP
occurred/VBN
can/MD
not/RB
block/VB
or/CC
slow/JJ
down/RB
disease/NN
progression/NN
[/(
8/CD
]/)
./.
====================
Instead/RB
,/,
many/JJ
reports/NNS
suggest/VBP
that/IN
earlier/RBR
treatment/NN
of/IN
TNF-α/NN
inhibitors/NNS
may/MD
prevent/VB
the/DT
progression/NN
of/IN
AS/JJ
more/RBR
effectively/RB
[/(
8910/CD
]/)
./.
====================
In/IN
our/PRP$
previous/JJ
work/NN
,/,
to/TO
identify/VB
AS-associated/JJ
SNP/NN
candidates/NNS
in/IN
Koreans/NNS
,/,
we/PRP
selected/VBD
seven/CD
AS-associated/JJ
SNP/NN
candidates/NNS
,/,
which/WDT
had/VBD
been/VBN
identified/VBN
in/IN
Caucasians/NNS
by/IN
a/DT
GWAS/JJ
and/CC
consistently/RB
replicated/VBN
in/IN
East/JJ
Asians/NNS
,/,
and/CC
performed/VBN
a/DT
replication/NN
study/NN
with/IN
285/CD
Korean/JJ
AS/JJ
cases/NNS
and/CC
363/CD
healthy/JJ
controls/NNS
[/(
11/CD
]/)
./.
====================
However/RB
,/,
in/IN
contrast/NN
to/TO
our/PRP$
expectation/NN
,/,
only/RB
one/CD
of/IN
them/PRP
was/VBD
replicated/VBN
in/IN
Koreans/NNS
./.
====================
In/IN
this/DT
study/NN
,/,
to/TO
identify/VB
other/JJ
AS-associated/JJ
SNP/NN
candidates/NNS
,/,
we/PRP
selected/VBD
three/CD
SNPs/NNS
in/IN
non-MHC/JJ
genes/NNS
from/IN
previous/JJ
GWASs/NNS
[/(
451213/CD
]/)
that/IN
are/VBP
associated/VBN
with/IN
AS/JJ
but/CC
have/VBP
not/RB
been/VBN
tested/VBN
in/IN
Koreans—rs11249215/NN
in/IN
RUNX3/NN
,/,
rs6556416/NN
in/IN
IL12B/NN
,/,
and/CC
rs8070463/NN
in/IN
TBKBP1—and/CC
examined/VBN
them/PRP
in/IN
a/DT
large/JJ
cohort/JJ
of/IN
Koreans/JJ
with/IN
AS/JJ
and/CC
healthy/JJ
controls/NNS
./.
====================
Study/NN
subjects/NNS
====================
A/DT
total/JJ
of/IN
1,138/NN
individuals/NNS
(/(
572/CD
AS/JJ
patients/NNS
and/CC
566/CD
healthy/JJ
controls/NNS
)/)
were/VBD
enrolled/VBN
in/IN
this/DT
study/NN
./.
====================
All/DT
of/IN
them/PRP
were/VBD
from/IN
our/PRP$
previous/JJ
CNV/NN
discovery/NN
study/NN
[/(
1113/CD
]/)
./.
====================
All/DT
AS/JJ
cases/NNS
were/VBD
diagnosed/VBN
according/VBG
to/TO
the/DT
Modified/JJ
New/NN
York/NN
Criteria/NN
[/(
14/CD
]/)
./.
====================
This/DT
study/NN
was/VBD
performed/VBN
with/IN
the/DT
approval/JJ
of/IN
the/DT
Institutional/JJ
Review/NN
Board/JJ
of/IN
the/DT
College/NN
of/IN
Medicine/NN
,/,
Catholic/JJ
University/NN
of/IN
Korea/NN
(/(
CUMC10U170/NN
)/)
./.
====================
The/DT
patients/NNS
were/VBD
aged/JJ
26.7/CD
±/CD
11.8/CD
years/NNS
(/(
85.3/CD
%/NN
male/JJ
and/CC
14.7/CD
%/NN
female/JJ
)/)
,/,
and/CC
97.9/CD
%/NN
of/IN
them/PRP
were/VBD
HLA-B27–positive/JJ
./.
====================
The/DT
controls/NNS
were/VBD
aged/JJ
23.9/CD
±/CD
11.8/CD
years/NNS
(/(
94.7/CD
%/NN
male/JJ
and/CC
5.3/CD
%/NN
female/JJ
)/)
,/,
and/CC
2.6/CD
%/NN
of/IN
them/PRP
were/VBD
HLA-B27–positive/JJ
./.
====================
SNP/NN
genotyping/VBG
====================
In/IN
this/DT
study/NN
,/,
we/PRP
selected/VBD
three/CD
SNPs/NNS
in/IN
non-MHC/JJ
genes/NNS
from/IN
previous/JJ
GWASs/NNS
[/(
4/CD
,/,
5/CD
,/,
1213/CD
]/)
that/IN
are/VBP
associated/VBN
with/IN
AS/JJ
but/CC
have/VBP
not/RB
been/VBN
tested/VBN
in/IN
Koreans/NNS
:/:
rs11249215/CD
in/IN
RUNX3/NN
,/,
rs6556416/NN
in/IN
IL12B/NN
,/,
and/CC
rs8070463/NN
in/IN
TBKBP1/NN
./.
====================
SNP/NN
genotyping/VBG
was/VBD
performed/VBN
using/VBG
the/DT
ViiA7/NN
system/NN
(/(
Life/NN
Technologies/NNS
,/,
Carlsbad/NN
,/,
CA/NNP
,/,
USA/NN
)/)
according/VBG
to/TO
the/DT
manufacturer/NN
's/POS
instructions/NNS
./.
====================
The/DT
thermal/JJ
cycling/NN
program/NN
included/VBD
one/CD
cycle/NN
at/IN
95℃/CD
for/IN
10/CD
min/NN
,/,
followed/VBN
by/IN
40/CD
cycles/NNS
at/IN
95℃/CD
for/IN
15/CD
s/NNS
and/CC
60℃/CD
for/IN
1/CD
min/NN
,/,
and/CC
a/DT
final/JJ
extension/NN
at/IN
60℃/CD
for/IN
30/CD
s./CC
Genotypes/NNS
were/VBD
determined/VBN
using/VBG
ViiA7/NN
software/RB
,/,
version/NN
1.2/CD
(/(
Life/NN
Technologies/NNS
)/)
./.
====================
Statistical/JJ
analysis/NN
====================
The/DT
differences/NNS
in/IN
allele/NN
and/CC
genotype/NN
frequencies/NNS
between/IN
cases/NNS
and/CC
controls/VBZ
were/VBD
assessed/VBN
using/VBG
chi-squared/JJ
test/NN
and/CC
Fisher/NN
exact/JJ
test/NN
./.
====================
Three/CD
genetic/JJ
models/NNS
(/(
dominant/JJ
,/,
recessive/JJ
,/,
and/CC
allele/NN
)/)
were/VBD
used/VBN
to/TO
test/VB
the/DT
SNP/NN
associations/NNS
./.
====================
Hardy-Weinberg/JJ
equilibrium/NN
had/VBD
been/VBN
tested/VBN
for/IN
all/DT
three/CD
SNPs/NNS
,/,
and/CC
their/PRP$
genotypes/NNS
were/VBD
in/IN
Hardy-Weinberg/JJ
equilibrium/NN
in/IN
our/PRP$
cohort/NN
./.
====================
Statistical/JJ
analyses/NNS
were/VBD
performed/VBN
using/VBG
PLINK/NN
[/(
15/CD
]/)
,/,
and/CC
p-values/NNS
less/RBR
than/IN
0.05/CD
were/VBD
considered/VBN
to/TO
be/VB
significant/JJ
in/IN
all/DT
statistical/JJ
analyses/NNS
./.
====================
To/TO
evaluate/VB
the/DT
candidate/NN
AS-associated/JJ
genetic/JJ
markers/NNS
,/,
we/PRP
selected/VBD
three/CD
SNPs/NNS
for/IN
a/DT
replication/NN
study/NN
in/IN
Koreans/NNS
(/(
rs11249215/NN
,/,
rs6556416/NN
,/,
and/CC
rs8070463/NN
)/)
that/WDT
have/VBP
been/VBN
previously/RB
reported/VBN
as/IN
risk/NN
factors/NNS
of/IN
AS/JJ
but/CC
have/VBP
not/RB
been/VBN
studied/VBN
in/IN
Koreans/NNS
./.
====================
All/DT
of/IN
them/PRP
were/VBD
located/JJ
in/IN
non-exonic/JJ
regions/NNS
:/:
rs11249215/CD
was/VBD
located/JJ
in/IN
the/DT
promoter/NN
of/IN
RUNX3/NN
,/,
rs6556416/NN
was/VBD
located/JJ
in/IN
the/DT
5'-flanking/JJ
region/NN
of/IN
IL-12B/NN
,/,
and/CC
rs8070463/NN
was/VBD
located/JJ
in/IN
the/DT
promoter/NN
of/IN
TBKBP1/NN
./.
====================
General/JJ
information/NN
on/IN
the/DT
three/CD
SNPs/NNS
is/VBZ
summarized/VBN
in/IN
Table/JJ
1/CD
./.
====================
We/PRP
performed/VBD
genotyping/VBG
assays/NNS
for/IN
the/DT
three/CD
SNPs/NNS
using/VBG
a/DT
total/JJ
of/IN
1,138/NN
Koreans/NNS
(/(
572/CD
AS/JJ
patients/NNS
and/CC
566/CD
healthy/JJ
controls/NNS
)/)
./.
====================
Minor/CC
allele/NN
frequencies/NNS
(/(
MAFs/NNS
)/)
of/IN
the/DT
three/CD
SNPs/NNS
in/IN
this/DT
study/NN
(/(
0.57/CD
for/IN
rs11249215/NN
,/,
0.91/CD
for/IN
rs6556416/NN
,/,
and/CC
0.44/CD
for/IN
rs8070463/NN
)/)
were/VBD
largely/RB
similar/JJ
to/TO
those/DT
in/IN
East/JJ
Asians/NNS
from/IN
the/DT
1000/CD
Genomes/NNS
Project/JJ
,/,
suggesting/VBG
that/IN
our/PRP$
genotyping/VBG
assays/NNS
were/VBD
reliable/JJ
(/(
Table/JJ
1/CD
)/)
./.
====================
In/IN
the/DT
association/NN
analysis/NN
,/,
one/CD
SNP/NN
in/IN
RUNX3/NN
(/(
rs11249215/NN
)/)
was/VBD
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
AS/JJ
in/IN
the/DT
recessive/JJ
model/NN
(/(
Table/JJ
2/CD
)/)
./.
====================
The/DT
MAF/NN
of/IN
rs11249215/NN
was/VBD
significantly/RB
higher/JJR
in/IN
AS/JJ
patients/NNS
(/(
MAF/NN
=/JJ
0.59/CD
)/)
than/IN
in/IN
controls/NNS
(/(
MAF/NN
=/JJ
0.56/CD
)/)
(/(
odds/NNS
ratio/NN
,/,
1.31/CD
;/:
95/CD
%/NN
confidence/NN
interval/JJ
,/,
1.02/CD
to/TO
1.68/CD
;/:
p/NN
=/JJ
0.03/CD
)/)
./.
====================
However/RB
,/,
significance/NN
was/VBD
not/RB
detected/VBN
in/IN
the/DT
allelic/JJ
or/CC
dominant/JJ
model/NN
for/IN
rs11249215/NN
./.
====================
The/DT
other/JJ
two/CD
SNPs/NNS
in/IN
IL-12B/NN
and/CC
TBKBP1/NN
showed/VBD
increased/VBN
odds/NNS
ratios/NNS
,/,
but/CC
they/PRP
were/VBD
not/RB
statistically/RB
significant/JJ
(/(
Table/JJ
2/CD
)/)
./.
====================
HLA-B27/NN
is/VBZ
the/DT
strongest/JJS
and/CC
most/JJS
well-known/JJ
genetic/JJ
factor/NN
of/IN
AS/JJ
./.
====================
However/RB
,/,
AS/JJ
develops/VBZ
in/IN
less/RBR
than/IN
5/CD
%/NN
of/IN
HLA-B27–positive/JJ
individuals/NNS
,/,
suggesting/VBG
the/DT
existence/NN
of/IN
additional/JJ
genetic/JJ
factors/NNS
./.
====================
Indeed/RB
,/,
a/DT
number/NN
of/IN
genetic/JJ
markers/NNS
in/IN
non-MHC/JJ
genes/NNS
have/VBP
been/VBN
identified/VBN
by/IN
SNP/NN
GWASs/NNS
and/CC
CNV/NN
GWASs/NNS
[/(
34567/CD
]/)
./.
====================
In/IN
this/DT
study/NN
,/,
we/PRP
performed/VBD
an/DT
SNP/NN
genotyping/VBG
assay/NN
to/TO
evaluate/VB
three/CD
AS-associated/JJ
SNP/NN
candidates/NNS
(/(
rs11249215/NN
in/IN
RUNX3/NN
,/,
rs6556416/NN
in/IN
IL12B/NN
,/,
and/CC
rs8070463/NN
in/IN
TBKBP1/NN
)/)
that/WDT
were/VBD
discovered/VBN
in/IN
Caucasians/NNS
but/CC
have/VBP
not/RB
been/VBN
studied/VBN
in/IN
Koreans/NNS
./.
====================
To/TO
generate/VB
more/RBR
reliable/JJ
data/NNS
,/,
we/PRP
used/VBD
a/DT
large/JJ
sample/JJ
set/NN
in/IN
this/DT
study/NN
(/(
572/CD
AS/JJ
patients/NNS
and/CC
566/CD
healthy/JJ
controls/NNS
)/)
./.
====================
To/TO
our/PRP$
knowledge/NN
,/,
this/DT
is/VBZ
the/DT
first/JJ
report/NN
of/IN
the/DT
association/NN
of/IN
these/DT
three/CD
SNPs/NNS
in/IN
Koreans/NNS
./.
====================
As/IN
a/DT
result/NN
,/,
rs11249215/NN
in/IN
RUNX3/NN
was/VBD
found/VBN
to/TO
be/VB
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
AS/JJ
in/IN
Koreans/NNS
./.
====================
However/RB
,/,
rs6556416/NN
in/IN
IL12B/NN
and/CC
rs4389526/NN
in/IN
ANTXR2/NN
were/VBD
not/RB
replicated/VBN
in/IN
Koreans/NNS
./.
====================
RUNX3/NN
(/(
Runt-related/JJ
transcription/NN
factor/NN
3/CD
)/)
is/VBZ
a/DT
member/NN
of/IN
a/DT
family/NN
of/IN
transcription/NN
factors/NNS
that/WDT
are/VBP
important/JJ
regulators/NNS
of/IN
lineage-specific/JJ
gene/NN
expression/NN
./.
====================
Woolf/PRP
et/FW
al/JJ
./.
====================
[/(
16/CD
]/)
demonstrated/VBD
that/IN
Runx3/NN
is/VBZ
highly/RB
expressed/VBN
in/IN
thymic/JJ
medulla/NN
and/CC
that/IN
it/PRP
promotes/VBZ
the/DT
differentiation/NN
of/IN
T/NN
cell/NN
to/TO
CD8+/JJ
T/NN
cells/NNS
during/IN
thymopoiesis/NN
./.
====================
More/RBR
recently/RB
,/,
RUNX3/NN
was/VBD
found/VBN
to/TO
be/VB
linked/VBN
to/TO
human/JJ
autoimmune/JJ
disease/NN
and/CC
inflammation/NN
./.
====================
For/IN
example/NN
,/,
Fainaru/NN
et/FW
al/JJ
./.
====================
[/(
17/CD
]/)
reported/VBD
that/IN
Runx3/NN
knockout/JJ
mice/NNS
develop/VBP
spontaneous/JJ
eosinophilic/JJ
lung/NN
inflammation/NN
,/,
which/WDT
is/VBZ
attributed/VBN
to/TO
dendritic/JJ
cells/NNS
becoming/VBG
insensitive/JJ
to/TO
transforming/VBG
growth/NN
factor/NN
β–induced/JJ
inhibition/NN
of/IN
maturation/NN
./.
====================
RUNX3/NN
polymorphisms/NNS
are/VBP
associated/VBN
with/IN
the/DT
susceptibility/NN
to/TO
autoimmune/JJ
diseases/NNS
,/,
such/JJ
as/IN
systemic/JJ
lupus/NN
erythematosus/NN
and/CC
psoriatic/JJ
arthritis/NN
[/(
1819/CD
]/)
./.
====================
Apel/NN
et/FW
al/JJ
./.
====================
[/(
18/CD
]/)
identified/VBD
that/WDT
RUNX3/NN
is/VBZ
involved/VBN
in/IN
CD8+/JJ
T/NN
lymphocyte/NN
differentiation/NN
and/CC
is/VBZ
related/JJ
to/TO
psoriatic/JJ
arthritis/NN
through/IN
a/DT
T/NN
cell–mediated/JJ
mechanism/NN
./.
====================
The/DT
association/NN
between/IN
the/DT
RUNX3/NN
polymorphism/NN
rs11249215/NN
and/CC
AS/JJ
has/VBZ
also/RB
been/VBN
reported/VBN
in/IN
Caucasian/JJ
[/(
4/CD
]/)
and/CC
Han/JJ
Chinese/JJ
populations/NNS
[/(
12/CD
]/)
./.
====================
Furthermore/RB
,/,
Vecellio/NNP
et/FW
al/JJ
./.
====================
[/(
20/CD
]/)
demonstrated/VBD
that/IN
rs4648889/NN
in/IN
RUNX3/NN
is/VBZ
associated/VBN
with/IN
AS/JJ
and/CC
that/IN
its/PRP$
risk/NN
allele/NN
reduces/VBZ
RUNX3/NN
expression/NN
./.
====================
Consistent/JJ
with/IN
previous/JJ
studies/NNS
,/,
in/IN
this/DT
study/NN
,/,
we/PRP
confirmed/VBD
that/IN
rs11249215/NN
in/IN
RUNX3/NN
is/VBZ
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
AS/JJ
in/IN
Koreans/NNS
in/IN
the/DT
recessive/JJ
model/NN
./.
====================
Because/IN
the/DT
homozygous/JJ
risk/NN
allele/NN
frequency/NN
is/VBZ
important/JJ
when/WRB
an/DT
SNP/NN
is/VBZ
a/DT
recessive/JJ
marker/NN
,/,
we/PRP
examined/VBD
the/DT
homozygous/JJ
risk/NN
allele/NN
frequency/NN
for/IN
rs11249215/NN
and/CC
found/VBD
that/IN
it/PRP
was/VBD
significantly/RB
higher/JJR
in/IN
AS/JJ
patients/NNS
(/(
homozygous/JJ
risk/NN
allele/NN
frequencies/NNS
[/(
HoF/JJ
]/)
=/JJ
0.36/CD
)/)
than/IN
in/IN
controls/NNS
(/(
HoF/NN
=/JJ
0.33/CD
)/)
(/(
Table/JJ
2/CD
)/)
./.
====================
Of/IN
note/NN
,/,
the/DT
MAF/NN
of/IN
rs11249215/NN
in/IN
controls/NNS
was/VBD
largely/RB
similar/JJ
to/TO
that/DT
in/IN
East/JJ
Asians/NNS
from/IN
the/DT
1000/CD
Genomes/NNS
Project/JJ
,/,
suggesting/VBG
that/IN
our/PRP$
study/NN
group/NN
was/VBD
not/RB
biased/VBN
and/CC
that/IN
the/DT
genotyping/VBG
was/VBD
appropriate/JJ
./.
====================
Because/IN
rs11249215/NN
is/VBZ
located/JJ
in/IN
the/DT
promoter/NN
of/IN
RUNX3/NN
,/,
further/RB
studies/NNS
on/IN
its/PRP$
molecular/JJ
effects/NNS
will/MD
help/VB
elucidate/VB
the/DT
pathogenesis/NN
of/IN
AS/JJ
./.
====================
In/IN
addition/NN
,/,
considering/VBG
that/DT
new/JJ
SNPs/NNS
are/VBP
being/VBG
reported/VBN
to/TO
be/VB
associated/VBN
with/IN
AS/JJ
,/,
other/JJ
replication/NN
studies/NNS
of/IN
newly/RB
identified/VBN
SNPs/NNS
are/VBP
also/RB
needed/VBD
./.
====================
In/IN
conclusion/NN
,/,
we/PRP
performed/VBD
a/DT
replication/NN
study/NN
of/IN
three/CD
SNPs/NNS
with/IN
a/DT
relatively/RB
large/JJ
cohort/JJ
of/IN
samples/NNS
and/CC
found/VBD
that/IN
rs11249215/NN
in/IN
RUNX3/NN
is/VBZ
significantly/RB
associated/VBN
with/IN
the/DT
risk/NN
of/IN
AS/JJ
in/IN
Koreans/NNS
./.
====================
These/DT
results/NNS
will/MD
be/VB
helpful/JJ
in/IN
elucidating/VBG
the/DT
pathogenesis/NN
of/IN
AS/JJ
and/CC
may/MD
be/VB
useful/JJ
for/IN
developing/VBG
risk/NN
prediction/NN
models/NNS
for/IN
AS/JJ
in/IN
Koreans/NNS
./.
====================
General/JJ
information/NN
for/IN
the/DT
three/CD
SNPs/NNS
====================
Association/NN
results/NNS
for/IN
the/DT
three/CD
SNPs/NNS
====================
